Diane T Stephenson

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Neuroimaging of pain: advances and future prospects
    Diane T Stephenson
    Pfizer Global Research and Development, Groton, Connecticut, USA
    J Pain 9:567-79. 2008
  2. ncbi Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species
    Diane T Stephenson
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Histochem Cytochem 57:933-49. 2009
  3. ncbi Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration
    Diane T Stephenson
    Pfizer Global Research and Development, Kalamazoo, MI 49007, USA
    Neurobiol Dis 20:347-59. 2005
  4. ncbi Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys
    Diane T Stephenson
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Cell Transplant 16:229-44. 2007
  5. ncbi Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection
    Diane Stephenson
    Pfizer Global Research and Development, Worldwide Safety Sciences and CNS Discovery, MS8274 1348, Eastern Point Road, Groton, CT 06340, United States
    J Neurosci Methods 159:291-9. 2007
  6. ncbi The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys
    Diane T Stephenson
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Pharmacol Exp Ther 314:1257-66. 2005
  7. ncbi A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats
    Frank S Menniti
    Neuroscience Biology, Pfizer Global Research and Development, Groton, CT, USA
    Restor Neurol Neurosci 30:283-9. 2012
  8. ncbi Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo
    Robin J Kleiman
    SystaMedic Inc, 1084 Shennecossett Drive, Groton, CT 06340, USA
    J Pharmacol Exp Ther 341:396-409. 2012
  9. ncbi Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species
    Timothy M Coskran
    PGRD Groton, MS 8274 1415, One Eastern Point Road, Groton CT 06340, USA
    J Histochem Cytochem 54:1205-13. 2006
  10. ncbi Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism
    Frank S Menniti
    Neuroscience Biology, Pfizer Global Research and Development, Groton, Connecticut, USA
    J Pharmacol Exp Ther 331:842-50. 2009

Detail Information

Publications10

  1. ncbi Neuroimaging of pain: advances and future prospects
    Diane T Stephenson
    Pfizer Global Research and Development, Groton, Connecticut, USA
    J Pain 9:567-79. 2008
    ..Emerging neuroimaging technologies may spawn new therapeutic approaches to treat chronic pain as well as define translational tools to assess functional clinical outcomes...
  2. ncbi Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species
    Diane T Stephenson
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Histochem Cytochem 57:933-49. 2009
    ..These studies suggest that PDE2A is evolutionarily conserved across mammalian species and support the hypothesis that the enzyme plays a fundamental role in signal transduction...
  3. ncbi Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration
    Diane T Stephenson
    Pfizer Global Research and Development, Kalamazoo, MI 49007, USA
    Neurobiol Dis 20:347-59. 2005
    ..The finding of elevated GAD67 expression in the pallidum is consistent with alterations in inhibitory neurocircuitry playing a key role in the pathophysiology of motor disturbances in Parkinson's disease...
  4. ncbi Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys
    Diane T Stephenson
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Cell Transplant 16:229-44. 2007
    ..These findings have implications for the use of biomarkers of disease progression as well as for the assessment of neurorestorative strategies, such as cell replacement, for the treatment of PD...
  5. ncbi Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection
    Diane Stephenson
    Pfizer Global Research and Development, Worldwide Safety Sciences and CNS Discovery, MS8274 1348, Eastern Point Road, Groton, CT 06340, United States
    J Neurosci Methods 159:291-9. 2007
    ....
  6. ncbi The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys
    Diane T Stephenson
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Pharmacol Exp Ther 314:1257-66. 2005
    ..These results suggest that sumanirole can exert antiparkinsonian effects similar to L-DOPA without the behavioral and morphological consequences of the latter...
  7. ncbi A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats
    Frank S Menniti
    Neuroscience Biology, Pfizer Global Research and Development, Groton, CT, USA
    Restor Neurol Neurosci 30:283-9. 2012
    ..To start to address this question, we determined whether PDE5A inhibitors must have the ability to cross the blood brain barrier to improve recovery...
  8. ncbi Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo
    Robin J Kleiman
    SystaMedic Inc, 1084 Shennecossett Drive, Groton, CT 06340, USA
    J Pharmacol Exp Ther 341:396-409. 2012
    ....
  9. ncbi Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species
    Timothy M Coskran
    PGRD Groton, MS 8274 1415, One Eastern Point Road, Groton CT 06340, USA
    J Histochem Cytochem 54:1205-13. 2006
    ..These data demonstrate that PDE10A is an evolutionarily conserved phosphodiesterase highly expressed in the brain but with restricted distribution in the periphery in multiple mammalian species...
  10. ncbi Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism
    Frank S Menniti
    Neuroscience Biology, Pfizer Global Research and Development, Groton, Connecticut, USA
    J Pharmacol Exp Ther 331:842-50. 2009
    ..Given the window for efficacy and the PDE5A distribution, we hypothesize that efficacy results from an effect on vasculature, and perhaps modulation of microglial function, both of which may facilitate recovery of neuronal function...